Tg Therapeutics, INC. (TGTX) — 10-Q Filings

All 10-Q filings from Tg Therapeutics, INC.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (5)

TG Therapeutics Soars on Revenue Growth, Tax Benefit — Nov 5, 2025 Risk: medium
TG Therapeutics, Inc. reported a significant increase in net income for the nine months ended September 30, 2025, reaching $424.142 million, a substantial rise
TG Therapeutics Sees Strong Revenue Growth in H1 2025 — Aug 8, 2025 Risk: medium
TG Therapeutics, Inc. reported product revenue of $158,786,335 for the six months ended June 30, 2025, a significant increase from $156,204,159 for the same per
TG Therapeutics Q1 2025: Assets $158.7M, Liabilities $155.8M — May 9, 2025 Risk: medium
TG Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $158.7 million and total liabilities of $155.8 m
TG Therapeutics Q3 2024: Assets Near Liabilities — Nov 7, 2024 Risk: medium
TG Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $155,910,901 and total liabilities of $155,7
TG Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 6, 2024 Risk: low
TG THERAPEUTICS, INC. (TGTX) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. TG Therapeutics, Inc. reported financial results for the quarter ended

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX